Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release therapies designed for ophthalmic use. Its current portfolio includes a marketed product for post-surgical ocular inflammation and pain, along with investigational therapies targeting retinal diseases, glaucoma, ocular hypertension, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix’s products and pipeline are centered on improving drug delivery in ophthalmology, where longer-acting formulations can help address treatment burden and support more consistent therapy administration. Based in Bedford, Massachusetts, the company operates in the specialty biopharmaceutical market with a strong emphasis on ocular care and retinal disease management.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Pravin U. Dugel M.D.

Employees

325

Headquarters

Bedford, MA, United States

Website

www.ocutx.com